Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 6/20 | 0.55 |
| ▸ | AXL | P30530 | 3/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.51 |
| ▸ | ULK1 | O75385 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CCNH | P51946 | 1/20 | 0.46 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL926536 | 1.00 | CDK8 (0.55) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| Hydrochloric Acid SCHEMBL28300266 | 0.98 | CDK8 (0.53) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL4294342 | 0.81 | PIK3CA (0.64) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL12127266 | 0.80 | RIPK1 (0.71) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL4831501 | 0.78 | CDK8 (0.81) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL23655689 | 0.77 | CDK8 (0.56) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL28863242 | 0.76 | CDK8 (0.52) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL857125 | 0.76 | CDK8 (0.69) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL1328372 | 0.76 | RIPK1 (0.49) | CDK8AXLPIK3CAPIK3CDPIK3CB | |
| SCHEMBL12148007 | 0.75 | CDK8 (0.55) | CDK8AXLPIK3CAPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697485-B | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-118976029-A | Pharmaceutical composition for preventing or treating parkinson's disease or nonalcoholic steatohepatitis | 韩国化学研究院 | 2024-11-19 | — | — | CN | disclosed |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-15 | — | — | US | disclosed |
| CN-114829344-B | Pyrimidine derivatives and pharmaceutical compositions containing the same | 韩国化学研究院 | 2024-08-13 | — | — | CN | disclosed |
| CN-111205310-B | Heterocyclic fused pyrimidine derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2023-11-02 | — | — | US | disclosed |
| CN-116745278-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116621860-A | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-111698989-B | Heterocyclic substituted pyridine derivatives as antifungal agents | 安普利克斯制药公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-111511748-B | Bcl-2 inhibitors | 广州麓鹏制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-4079726-A1 | NOVEL PYRIMIDIN DERIVATIVE AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2022-10-26 | — | — | EP | disclosed |
| EP-4070795-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-114829344-A | Novel pyrimidine derivative and use thereof | 韩国化学研究院 | 2022-07-29 | — | — | CN | disclosed |
| CN-109071565-B | Tricyclic heterocyclic derivatives | 默克专利股份公司 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | CDK8 478/4885AXL 1342/4885PIK3CA 1039/4885 |
| US-20230348399-A1 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | CDK8 478/4885AXL 1342/4885PIK3CA 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.